Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Inclusion Criteria:

• Histologically or cytologically documented Stage IV metastatic, NSCLC

• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1

• At least one measurable target lesion per RECIST v1.1.

• Adequate organ function

• Participants must be willing to provide adequate tumor tissue

Exclusion Criteria:

• Underlying medical conditions that, in the Investigator's or Sponsor's opinion, willmake the administration of Investigational Product(s) (IPs) hazardous

• Use of any live vaccines against infectious diseases within 28 days of first dose ofIP(s).

• Use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone orequivalent) or immunosuppressive medications ≤ 14 days before the initiation ofstudy treatment (absorbable topical corticosteroids are not excluded).

• Has known psychiatric or substance abuse disorders that would interfere withcooperation with the requirements of the trial.

• Any active autoimmune disease or a documented history of autoimmune disease orsyndrome that required systemic treatment in the past 2 years (ie, with use ofdisease-modifying agents, corticosteroids, or immunosuppressive drugs), except forvitiligo or resolved childhood asthma/atopy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.